References
- Gerard-Marchant R., Hamlin I., Lennert K. Classification of non-Hodgkin's lymphoma. Lancet 1974; ii: 406–408
- Stansfeld A. G., Diebold J., Noel H., Kapanci Y., Rilke F., Kelenyi G., Sundstrom C., Lennert K., van Unnik J. A.M., Mioduszewska O., Wright D. H. Updated Kiel classification for lymphomas [letter]. Lancet 1988; 1: 292–293
- Gallagher C. J., Gregory W. M., Jones A. E., Stansfeld A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 1986; 4: 1470–1480
- Richards M. A., Hall P. A., Gregory W. M., Dhaliwal H. S., Stansfeld A. G., Amess J. A., Lister T. A. Lymphoplasmacytoid and small cell centrocytic non-Hodgkin's lymphoma-a retrospective analysis from St. Bartholomew's Hospital 1972–1986. Hematol. Oncol. 1989; 7: 19–35
- Tidd T. M. Antipurines. Handbook of Experimental Pharmacology, B. W. Fox, M. Fox. Antitumor Drug Resistance, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo 1984; 72: 445–493
- Brockman R. W., Cheng Y. C., Schabel F. J., Montgomery J. A. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphoryla-tion by deoxycytidine kinase. Cancer Res. 1980; 40: 3610–3615
- Dow L. W., Bell D. E., Poulakos L., Fridland A. Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofur-anosyl-2-fluoroadenine in human Icukemic lymphoblasts. Cancer Res. 1980; 40: 1405–1410
- Plunkett W., Chubb S., Alexander L., Montgomery J. A. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. 1980; 40: 2349–2355
- Chun H. G., Leyland J. B., Caryk S. M., Hoth D. F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep. 1986; 70: 1225–1228
- Chun H. G., Leyland J. B., Cheson B. D. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J. Clin. Oncol. 1991; 9: 175–188
- Leiby J. M., Snider K. M., Kraut E. H., Metz E. N., Malspeis L., Grever M. R. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res. 1987; 47: 2719–2722
- Redman J. R., Cabanillas F., Velasquez W. S., Mc-Laughlin P., Hagemeister F. B., Swan F., Rodriguez M. A., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
- Hochster H., Kim K., Green M. D., Mann R. B., Nei-man R. S., Oken M. S., Cassileth P. A., Stott P., Ritch P., O'Connell M. J. Activity of fludarabine in previously treated non-Hodgkin's low grade lymphoma: results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1992; 10: 28–32
- Whelan J. S., Davis C. L., Rule S., Ranson M., Smith O. P., Mehta A. B., Catovsky D., Rohatiner A., Lister T. A. Fludarabine phosphate for the treatment of low-grade lymphoid malignancy. Br. J. Cancer 1991; 64: 120–123